Merck Protease Inhibitor Impresses At EASL, Anadys Suffers Rash Concerns
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The second-generation protease inhibitors for hepatitis C could have a tough time competing with the lead agents in the class, Vertex's telaprevir and Schering-Plough's boceprevir - as data presented at the European Association for the Study of the Liver's recent meeting reveals safety problems with some of the products in earlier stage development
You may also be interested in...
New Data Shed Further Light on HCV Protease Race
Final Phase II data have set the stage for the ultimate chapter in a compelling race to develop the first hepatitis C protease inhibitor. These first-generation molecules - Vertex's telaprevir and Schering-Plough's boceprevir - are not perfect, but look likely to significantly improve HCV cure rates and establish shorter durations for difficult-to-take therapeutic regimens
INFORM-1 Data Show Potential Efficacy And Safety Of Roche HCV Combo
Combination therapy with two experimental, oral, direct-acting antivirals in treatment-naïve hepatitis C patients showed significant viral-load reductions and a clean safety profile, Roche and its biotech partners on the two drugs announced April 25 during the European Association for the Study of the Liver conference in Copenhagen, Denmark.
New Data Shed Further Light on HCV Protease Race
Final Phase II data have set the stage for the ultimate chapter in a compelling race to develop the first hepatitis C protease inhibitor. These first-generation molecules - Vertex's telaprevir and Schering-Plough's boceprevir - are not perfect, but look likely to significantly improve HCV cure rates and establish shorter durations for difficult-to-take therapeutic regimens